Tacrolimus: in heart transplant recipients

Area of Science:

• Immunosuppression
• Transplantation Medicine
• Pharmacology

Background:

• Tacrolimus is a calcineurin inhibitor used for immunosuppression.
• It is approved for preventing allograft rejection in heart transplant recipients.
• Oral administration is common for long-term use.

Purpose of the Study:

• To evaluate the efficacy and tolerability of tacrolimus in heart transplant recipients.
• To compare tacrolimus with ciclosporin in preventing acute rejection.
• To assess long-term patient survival and adverse events.

Main Methods:

• Large-scale, phase III clinical trials conducted in Europe and the US.
• Comparison of tacrolimus versus ciclosporin for immunosuppression post-heart transplantation.
• Monitoring of rejection incidence, patient survival, and adverse events.

Main Results:

• Significantly lower incidence of mild to severe acute rejection in the first 6 months in EU trials (54% vs 66%).
• US trials showed no significant difference in severe rejection within 6 months, but a significant difference at 1 year (23% vs 37%).
• 1-year patient survival was similar (EU: 93% vs 92%; US: 95% vs 90%). Tacrolimus demonstrated efficacy in pediatric and African American recipients and had a similar tolerability profile, with lower incidences of post-transplant hypertension and dyslipidaemia.

Conclusions:

• Tacrolimus is effective in preventing allograft rejection in heart transplant recipients.
• It offers comparable patient survival to ciclosporin.
• Tacrolimus presents a favorable tolerability profile, with reduced risks of hypertension and dyslipidaemia.